[go: up one dir, main page]

BR9710918A - Method of treatment or reduction of myocardial ischemia or arteriocoronary disease or cardiovascular accidents and use of progesterone and cross-linked mpolicarboxylic acid polymer. - Google Patents

Method of treatment or reduction of myocardial ischemia or arteriocoronary disease or cardiovascular accidents and use of progesterone and cross-linked mpolicarboxylic acid polymer.

Info

Publication number
BR9710918A
BR9710918A BR9710918-5A BR9710918A BR9710918A BR 9710918 A BR9710918 A BR 9710918A BR 9710918 A BR9710918 A BR 9710918A BR 9710918 A BR9710918 A BR 9710918A
Authority
BR
Brazil
Prior art keywords
progesterone
disease
arteriocoronary
treatment
cross
Prior art date
Application number
BR9710918-5A
Other languages
Portuguese (pt)
Inventor
Howard L Levine
William J Bologna
Original Assignee
Columbia Lab Bermudas Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24987712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9710918(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Columbia Lab Bermudas Limited filed Critical Columbia Lab Bermudas Limited
Publication of BR9710918A publication Critical patent/BR9710918A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<B>MéTODO DE TRATAMENTO OU REDUçãO DE ISQUEMIA DE MIOCáRDIO OU DOENçA ARTERIOCORONáRIA OU ACIDENTES CARDIOVASCULARES E USO DE PROGESTERONA E POLìMERO DE áCIDO POLICARBOXìLICO DE LIGAçãO CRUZADA<D>. A presente invenção compreende a administração de progesterona para tratar ou reduzir isquemia ou incidência de acidentes cardiovasculares, ou para tratar doença arterial coronária. Está demonstrado que a progesterona, à diferença das progestinas sintéticas, reduz a isquemia. Portanto, a progesterona, por exemplo, mas não as progestinas sintéticas, pode ser utilizadas em terapia de reposição de hormónio com efeitos positivos, e não negativos, no tratamento da isquemia.<B> METHOD OF TREATING OR REDUCING MYOCARDIAL ISCHEMIA OR ARTERIOCORONARY DISEASE OR CARDIOVASCULAR ACCIDENTS AND USE OF PROGESTERONE AND CROSS-BINDING POLYCARBOXYLIC ACID POLYMER <D>. The present invention comprises the administration of progesterone to treat or reduce ischemia or incidence of cardiovascular accidents, or to treat coronary artery disease. Progesterone, unlike synthetic progestins, has been shown to reduce ischemia. Therefore, progesterone, for example, but not synthetic progestins, can be used in hormone replacement therapy with positive, rather than negative, effects in the treatment of ischemia.

BR9710918-5A 1996-11-04 1997-11-04 Method of treatment or reduction of myocardial ischemia or arteriocoronary disease or cardiovascular accidents and use of progesterone and cross-linked mpolicarboxylic acid polymer. BR9710918A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/743,153 US5985861A (en) 1996-11-04 1996-11-04 Progesterone for treating or reducing ischemia
PCT/US1997/020923 WO1998019681A1 (en) 1996-11-04 1997-11-04 Progesterone for treating or reducing ischemia

Publications (1)

Publication Number Publication Date
BR9710918A true BR9710918A (en) 2000-01-11

Family

ID=24987712

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9710918-5A BR9710918A (en) 1996-11-04 1997-11-04 Method of treatment or reduction of myocardial ischemia or arteriocoronary disease or cardiovascular accidents and use of progesterone and cross-linked mpolicarboxylic acid polymer.

Country Status (26)

Country Link
US (2) US5985861A (en)
EP (1) EP0956023B1 (en)
KR (1) KR100434623B1 (en)
CN (1) CN100341512C (en)
AR (1) AR009407A1 (en)
AT (1) ATE321558T1 (en)
AU (1) AU715740C (en)
BR (1) BR9710918A (en)
CA (1) CA2270565C (en)
DE (1) DE69735598T2 (en)
DK (1) DK0956023T3 (en)
ES (1) ES2262196T3 (en)
GE (1) GEP20022630B (en)
HU (1) HUP9904045A3 (en)
IL (1) IL127455A (en)
LV (1) LV12342B (en)
MA (1) MA24391A1 (en)
MY (1) MY121627A (en)
NO (1) NO324278B1 (en)
NZ (1) NZ335306A (en)
PE (1) PE9899A1 (en)
PT (1) PT956023E (en)
RO (1) RO120607B1 (en)
UA (1) UA66772C2 (en)
WO (1) WO1998019681A1 (en)
ZA (1) ZA979862B (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6056972A (en) * 1997-02-26 2000-05-02 Dimera, Llc Method for reducing coronary artery reactivity
US6602487B1 (en) 1997-02-26 2003-08-05 Dimera Incorporated Methods and tests for producing and for inhibiting coronary artery vasospasms
DE69819748T2 (en) 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. MEDICINES FOR TREATING DYSMENORRHEA AND PREVIOUS BLIES
US20040234606A1 (en) * 1997-09-12 2004-11-25 Levine Howard L. Localized vaginal delivery without detrimental blood levels
GB0107383D0 (en) * 2001-03-23 2001-05-16 Univ Edinburgh Lipid profile modulation
US20030114394A1 (en) * 2001-10-29 2003-06-19 Levine Howard L. Vaginally administered anti-dysrhythmic agents for treating pelvic pain
US8425892B2 (en) 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
US20080182841A1 (en) * 2001-10-29 2008-07-31 Levine Howard L Vaginally administered anti-dysrhythmic agents for treating pelvic pain
US7572780B2 (en) 2003-01-21 2009-08-11 Dimera, Incorporated Method and kit for reducing the symptoms of peripheral vascular disease
JP4898431B2 (en) * 2003-04-29 2012-03-14 ザ ジェネラル ホスピタル コーポレイション Methods and devices for sustained release of multiple drugs
DE102005027004B4 (en) * 2005-06-10 2020-03-19 Continental Automotive Gmbh Windshield washer
US8828981B2 (en) 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
KR20100133969A (en) * 2008-02-04 2010-12-22 테바 위민즈 헬스 인코포레이티드 Progesterone-containing single vaginal ring and its preparation method and use
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
KR20170040209A (en) 2014-07-29 2017-04-12 쎄러퓨틱스엠디, 인코퍼레이티드 Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11512107B2 (en) 2018-09-07 2022-11-29 Trustees Of Dartmouth College Methods for assembly of tetracyclic compounds by stereoselective C9-C10 bond formation
AU2019335005A1 (en) 2018-09-07 2021-03-18 Trustees Of Dartmouth College C19 scaffolds and steroids and methods of use and manufacture thereof
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
GB202316026D0 (en) * 2023-10-19 2023-12-06 Theramex Hq Uk Ltd Methods of prevention or treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1124906A1 (en) * 1982-05-25 1984-11-23 Ивановский государственный медицинский институт им.А.С.Бубнова Method of correcting ischemia injuries of preserved donor's kidney
JPH0830004B2 (en) * 1983-11-14 1996-03-27 コロンビア ラボラトリーズ インコーポレイテッド Bioadhesive composition and method of treatment therewith
US5543150A (en) * 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof

Also Published As

Publication number Publication date
LV12342A (en) 1999-09-20
NO992140D0 (en) 1999-05-03
KR20000053056A (en) 2000-08-25
IL127455A0 (en) 1999-10-28
WO1998019681A1 (en) 1998-05-14
ES2262196T3 (en) 2006-11-16
AR009407A1 (en) 2000-04-12
US5985861A (en) 1999-11-16
GEP20022630B (en) 2002-02-25
NZ335306A (en) 2000-12-22
CA2270565A1 (en) 1998-05-14
NO992140L (en) 1999-05-04
IL127455A (en) 2005-03-20
MY121627A (en) 2006-02-28
DE69735598D1 (en) 2006-05-18
DE69735598T2 (en) 2006-12-28
CA2270565C (en) 2007-02-20
NO324278B1 (en) 2007-09-17
HUP9904045A2 (en) 2000-04-28
PE9899A1 (en) 1999-02-08
ATE321558T1 (en) 2006-04-15
HUP9904045A3 (en) 2000-11-28
HK1020534A1 (en) 2000-05-12
DK0956023T3 (en) 2006-08-07
MA24391A1 (en) 1998-07-01
KR100434623B1 (en) 2004-06-05
LV12342B (en) 2000-01-20
ZA979862B (en) 1998-05-25
EP0956023A1 (en) 1999-11-17
PT956023E (en) 2006-08-31
AU715740C (en) 2004-04-29
AU715740B2 (en) 2000-02-10
RO120607B1 (en) 2006-05-30
CN1235549A (en) 1999-11-17
EP0956023B1 (en) 2006-03-29
US6054447A (en) 2000-04-25
AU5180198A (en) 1998-05-29
CN100341512C (en) 2007-10-10
UA66772C2 (en) 2004-06-15

Similar Documents

Publication Publication Date Title
BR9710918A (en) Method of treatment or reduction of myocardial ischemia or arteriocoronary disease or cardiovascular accidents and use of progesterone and cross-linked mpolicarboxylic acid polymer.
CA2328368A1 (en) Anti-inflammatory agents
AU2310088A (en) Hemorrhoidal, other compositions and methods of treatment
BR9006924A (en) FORMULATION FOR THE TREATMENT OF SYMPTOMS AND DISEASES, USE OF FORMULATION FOR THE TREATMENT OF SYMPTOMS AND DISEASES, METHOD FOR THE TREATMENT OF SYMPTOMS AND DISEASES, DISTRIBUTION OF MEDICINAL AND THERAPEUTIC AGENTS FOR THE TREATMENT OF SYMPTOMS AND DISEASES IN COMBINATION
PT930876E (en) USING SEXUAL STEROID FUNCTION MODULATORS FOR TREATING FIBROTIC WOUNDS AND DISORDERS
BR9707325A (en) Process for the treatment of an affected patient with an il-1-mediated disease, pharmaceutical composition and use
NO951592L (en) Process for the preparation of a transdermal therapeutic system
BR0206985A (en) Modified Antibodies and Methods of Use
FR2777183B1 (en) USE OF AT LEAST ONE HYDROXYSTILBENE IN A COMPOSITION FOR PROMOTING DEQUAMATION OF THE SKIN AND COMPOSITION COMPRISING SAME
EP0378086A3 (en) Use of the agent azelastine in the treatment of psoriasis
AR015933A1 (en) ENAMEL FOR ONE WITH ANTIPSORIASIC ACTIVITY AND PROCEDURE FOR PREPARATION
GR3031250T3 (en) Methods of diagnosing and treating preeclampsia
ES2042742T3 (en) PROCEDURE FOR PREPARING ANTI-INFLAMMATORY PURANONES.
MX9603596A (en) Prevention and treatment of topical viral infections with perfluoropolyether compounds and compositions including perfluoropolyether compounds.
BR9912773A (en) Process and apparatus for the topical treatment of diseased tissue and process for the treatment of diseases in circulatory system vessels
BR0111506A (en) Macromolecular drug complexes and compositions containing same
SE9603725D0 (en) New teatment
BG101126A (en) The use of muramylpeptide compounds
DE69125855D1 (en) THERAPEUTICALLY EFFECTIVE, LOCAL APPLICATION OF ST1435
ATE137737T1 (en) 2-AMINO-1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES WITH AN EFFECT ON THE CARDIOVASCULAR SYSTEM, METHOD FOR THE PRODUCTION THEREOF AND THEIR PHARMACEUTICAL COMPOSITIONS
Wollenberg et al. Acne conglobata and Klinefelter's syndrome
EP0279867A3 (en) Use of vitamin e and combinations of vitamin e with anti-inflammatory agents and analgesics in the treatment of rheumatic diseases
ES2211996T3 (en) UNION AGENTS FOR HIALURONIC ACID RECEPTORS AND THEIR USE FOR TUMOR TREATMENT OR RESISTANCE.
UA39179C2 (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HEART RATE DISORDERS IN LARGE MAMMALS AND HUMANS, METHOD OF PREPARATION AND ANTIARRHYMATIC
NO962619D0 (en) psoriasis Treatment

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADO DE INT.CL: A61K 31/57; A61K 31/565; A61P 9/10

Ipc: A61K 31/57 (2008.01), A61K 31/565 (2008.01), A61P

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI